bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prognostic value of serum IL‐10 and soluble IL‐2 receptor levels in aggressive non‐Hodgkin's lymphoma
Authors: Stasi Roberto , Zinzani Pier Luigi , Galieni Piero , Lauto Vito Michele , Damasio Eugenio , Dispensa Egidio , Dammacco Franco , Papa Giuseppe , Tura Sante 
Published: March 2008

SummaryWe investigated the prognostic significance of interleukin‐10 (IL‐10) and soluble interleuckin‐2 receptor (sIl‐2r) levles in the pretreatment serum of 105 individuals with newly‐diagnosed aggressive non‐Hodgkin's lymphoma (NHL). Commercially available enzyem‐linked immunoassay kits were used for cytokine and receptor measurements. Detectable levels of IL‐10 were found in 42 (40%) patients at diagnosis, with no correlation with clinico‐haematological parameters, but in no control samples (P < 0.001).Pretreatment concentrations of sIL‐2r were markedly increased in individuals with NHL when compared to controls (2614 ± 893 U/ml v 219 ± 65U/ml, P < 0.001), patients with stage III/IV presenting higher values than those with stage II disase (3885 ± 1196U/ml v 1732 ± 646U/ml, P < 0.001). No single parameter was associated with the achiveement of complete remission, but the combination of elevated IL‐10 and of sIL‐2r greater than 3000U/ml selected a subset of patients with a high probability of failing induction therapy (P < 0.001). Lifetable analysis also indicated thatj patients with these characteristics have a significantly shorter event‐free survival. In a multivariate analysis the combination of IL‐10 with sIL‐2r was found to have greater predictive strength than the combination of IL‐10 with β2‐micro‐globulin. We conclude that IL‐10 and sIL‐2r measurements can be expected to improve existing methods of risk assignment in aggressive NHL.
Blast cells in child and adult AML: comparative study of morphocytochemical, immunological and cytogenetic characteristics
Authors: Frenkel M. A. , Tupitsyn N. N. , Protasova A. K. , Kadagidze Z. G. , Konstantinova L. N. , Fleischman E. W. 
Published: March 2008

SummaryBone marrow blast cells of 174 child and 188 adult patients with AML were examined and characterized in terms of their FAB type, immunological phenotype (102 children, 123 adults) and karyotype (69 children, 95 adults). The incidence of FAB variants of AML proved similar in children and adults. In patients under 15 and over 60, peroxidase activity in myeloblasts was lower than in middle‐aged patients. Similar rates of HLA‐Dr, Thy‐1, CD11a, T‐cell antigens, CD19, Gly‐A and Eb antigens were found in cells of child and adult patients. The frequency of CD11b, CD38 and CD10 antigen expression on blast cells was higher in children than in adults. Abnormal blast karyotype was noted in 81.8% of children and 73.7% of adults. Translocation (8;21) was usually found in cases of M2 type (82%), significantly more frequently in children, predominantly in the group aged 6‐10. t(15;17) was detected in all age groups only in M3 type of cells (86%), t(9;22) occurred more frequently in adults than in children; t(11q23) incidence rates were somewhat higher in children than in adults. Three cases of AML in children are described with deletion of chromosome 5 in their leukaemic cells. The data obtained indicate different biological characteristics of blast cells in children and adults. It is likely that haemopoietic cell involvement in children under 2 years and adult patients over 60 occurs at earlier stages than in middle‐aged patients.
Nondeletional type of hereditary persistence of fetal haemoglobin: molecular characterization of three unrelated Thai HPFH
Authors: Winichagoon Pranee , Fucharoen Suthat , Wilairat Prapon , Chihara Kazuo , Fukumaki Yasuyuki 
Published: March 2008

SummaryThe β‐globin gene clusters of three unrelated Thai families with a nondeletional type of hereditary persistence of fetal haemoglobin (HPFH) were studied using polymerase chain reaction‐related techniques. All appeared to have normal nucleotide sequences from the Cap site to position ‐400 of both the Gγ‐ and Aγ‐globin genes. Two individuals suspected of having a β‐thalassaemia gene linked to the high HbF condition also had a normal β‐globin gene sequence, spanning from position ‐108 from the Cap site to the polyadenylation site. Deletion of four nucleotides, AGCA, at positions ‐225 to ‐222 of one Aγ‐globin allele was detected in one subject and was confirmed by dot‐blot hybridization. Restriction fragment length polymorphisms in the β‐globin gene cluster showed that the 5’ haplotype (‐ + ‐ ++) and the presence (+) of an Xmn 1 polymorphic site at ‐158 of the Gγ‐globin gene are associated with the high F phenotype in these families. Direct sequencing of the 5’ hypersensitive‐2 (5’ HS‐2) site of the locus control region (LCR) showed that this Xmn, 1 (+) site is also linked to a specific rearrangement of TA repeats (TA)9CACATATACG(TA)10, in HS‐2 segment.
Analysis of immunoglobulin class, IgG subclass and titre of HPA‐1a antibodies in alloimmunized mothers giving birth to babies with or without neonatal alloimmune thrombocytopenia
Authors: Proulx Chantal , Filion Mario , Goldman Mindy , Bradley Amanda , Devine Dana , Décary Francine , Chartrand Pierre 
Published: March 2008

SummaryWe analysed the titre and isotype composition of antibodies produced by mothers giving birth to babies with or without neonatal alloimmune thrombocytopenic purpura (NAITP) and patients with post‐transfusion purpura (PTP). All these individuals produced an antibody specific for the HPA‐1a allotype present on the platelet glycoprotein IIb‐IIIa (GPIIb‐IIIa). Sera from mothers who gave birth to thrombocytopenic babies (group 1, n = 36), non‐thrombo‐cytopenic babies (group 2, n = 4) or from PTP patients (group 3, n = 3) were tested by an indirect‐ELISA. Results indicated no evident differences in the isotype composition or titre of the antibodies from the three groups of sera. The antibody titre ranged from 1: 120 to 1: 3500. Antibodies with the IgGl subclass were present in all sera. Most sera contained IgGl alone (24/43 sera tested) or in combination with IgG3 (10/43). IgG2 was never present and only three sera showed intermediate reactivity with anti‐IgG4 MAb. Few sera (nine sera from groups 1 and 2) were weakly positive when tested with the anti‐IgM antibodies. These results suggest that neither the titre nor the isotype composition can be used to predict the severity or the occurrence of thrombocytopenia in newborns.
Acquired sideroblastic anaemia following progesterone therapy
Authors: Brodsky Robert A. , Hasegawa Setsuo , Fibach Eitan , Dunber Cynthia E. , Young Neal S. , Rodgers Griffin P. 
Published: March 2008

SummaryWe report a case of acquired sideroblastic anaemia precipitated by progesterone. On two separate occasions, over 15 years apart, the patient developed sideroblastic anaemia with iron overload shortly after the administration of progesterone. No other cause for sideroblastic anaemia was found, and treatment with folic acid, pyridoxine or androgens corrected the anaemia. In both instances removal of the progestational agent led to prompt disappearance of the anaemia as well as the ringed sideroblasts. Using a two‐phase liquid culture procedure in which human peripheral blood‐derived progenitor cells undergo erythroid proliferation and differentiation. we demonstrated enhanced sensitivity of the patient's erythroid progenitors to progesterone. We conclude that progesterone should be added to the list of medications known to be associated with acquired sideroblastic anaemia.
Peripheral T‐cell non‐Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T‐zone lymphoma
Authors: Siegert Wolfgang , Nerl Christoph , Engelhard Marianne , Brittinger Günter , Tiemann Markus , Parwaresch Reza , Heinz Renate , Huhn Dieter 
Published: March 2008

SummaryPeripheral T‐cell lymphomas comprise a heterogenous group of low‐ and high‐grade malignancies differing in their histopathological appearance and also in clinical and prognostic aspects. We prospectively studied 25 patients with low‐grade peripheral T‐cell lymphomas: pleomorphic, small cell lymphoma (PSC) (n = 9), lymphoepitheloid (Lennert's) lymphoma (LEL) (n= 12) and T‐zone lymphoma (TZL) (n= 4). The median patient age was 55 years (range 19‐75 years); the male to female ratio was 1.5. 13 patients (52%) had limited stages (I + II), 12 patients (48%) had advanced disease (stage III + IV). 21 patients received the COPBLAM/IMVP‐16 regimen. Two patients received more intensive treatments; two received less intensive therapy. Complete remissions were achieved in 16/25 patients (64%). The median observation time of surviving patients was 30 months (range 5‐72 months). The actuarial overall survival and event‐free survival at 2 years of 21 patients receiving COPBLAM/IMVP‐16 were 69% and 35%, respectively. Intensive chemotherapy led to complete remissions in about 60% of the patients and to long‐term disease‐free survival for one‐third. The observed clinical courses illustrate the aggressive nature of PSC, LEL and TZL.
Improvement of mitomycin C‐ and cyclophosphamide‐induced thrombocytopenia and leucocytopenia by prior treatment with deoxyspergualin in dogs
Authors: Nemoto Kyuichi , Ogino Miwa , Sugawara Yumi , Abe Fuminori , Ito Junpei , Takeuchi Tomio 
Published: March 2008

SummaryDeoxyspergualin (DGS) is a new immunosuppressant which has shown inhibitory haemopoietic activity. We investigated the myeloprotective effect of DSG against the haemopoietic injury of mitomycin C (MMC) or cyclophosphamide (CYC) by measuring peripheral blood cell numbers in dogs. DSG given at 5 mg/kg on days 3, 2 and 1 before, or at 10 mg/kg on either days 2 and 1 before or on day 1 before and the day of injection of MMC at 0.25 mg/kg ameliorated both the thrombocytopenia and leucopenia caused by MMC. This ameliorative effect was more evident on platelet counts than on white blood cell counts. In addition, the leucopenia and thrombocytopenia induced by a single injection of CYC at 10 mg/kg was also ameliorated by prior DSG administration. These findings suggest that DSG may be useful in protecting against the haemopoietic damage induced by chemotherapeutic agents in the treatment of cancer.
G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft
Authors: Dreger Peter , Haferlach Torsten , Eckstein Volker , Jacobs Sophia , Suttorp Meinolf , Löuffler Helmut , And Wolfgang Müller‐Ruchholtz , Schmitz Norbert 
Published: March 2008

SummaryAllogeneic transplantation of peripheral blood progenitor cells (PBPC) markes the general anaesthesia of the donor unnecessary and may result in more rapid engraftment and faster recovery of the immune system. We have studied G‐CSF‐mediated PBPC mobilization in healthy donors and analysed the cellular composition of the resulting PBPC grafts. PBPC grafts were obtained from nine healthy donors (18‐67 years old) for allogeneic or syngeneic transplantation. Six donors received 10 μg/kg G‐CSF per day, the others 5‐6 μg/kg. Mobilization and harvesting were well tolerated except for moderate bone pain which occurred in all donors primed with 10 μg/kg. With 10 μg/kg, a 31‐fold (9‐62) enrichment of circulating CD34+ cells was observed with peak values constantly occurring on day 5 after the start of G‐CSF administration. Starting harvest on day 5, one to three collections on consecutive days yielded 5.5 x 106/kg (0.9‐10.7) CD34+ cells, 219 x 106/kg (106–314) T cells, and 34 x 106/kg (23–67) NK cells per 10 litres leukapheresis volume. Altogether, PBPC grafts contained 3 times more CD34+ cells, 7 times more T cells, and 20 times more NK cells than five allogeneic marrow grafts that were analysed for comparison. The yield of CD34+ cells per 10 litres apheresis volume as well as the height of the CD34+ peak in peripheral blood were inversely correlated to the age of the donor. In the donors primed with 5–6μg/kg G‐CSF the increase of circulating CD34+ cells (4–7‐fold enrichment) and the CD34+ cell yield per 10 litres leukapheresis volume (1 x 106/kg [0.8‐2‐2]) was much smaller compared with the 10μg/kg group. In conclusion, sufficient amounts of PBPC capable of restoring haemopoiesis in allogeneic recipients can be mobilized safely by administration of G‐CSF (10 μg/kg s.c. for 5 d) in healthy donors, and harvested with one or two leukapheresis procedures. Whether the large numbers of T‐cells and NK cells that are contained in the collection products may influence graft‐versus‐host and graft‐versus‐leukaemia reactivities of PBPC grafts remains to be determined.
Red cell lipid abnormalities in acquired acanthocytosis are extended to platelets
Authors: Ulibarrena Carlos , And Ana Vecino , Cesar Jesüas M. 
Published: March 2008

SummaryAcquired acanthocytosis (AA) is an uncommon disease characterized by the presence of abnormal red cells (acanthocytes) in the blood smears of affected subjects. Acanthocyte membrane is enriched in cholesterol by an abnormal plasma lipoprotein. We studied the existence of similar changes in platelets of one patient with AA. Red cell cholesterol/phospholipid (Ch/PL) ratio in the patient was 1.6 (normal 1.1 ± 0.1). Phosphatidylcholine (PC) comprised 36% of total phospholipid (30.7 ± 1.8% in controls). Platelets showed aberrant morphology in the blood smears, and the ratio Ch/PL was high in comparison with normal platelets (1.4v 0.6 ± 0.1). PC comprised 52% of total PL (39.6 ± 1.9% in normal platelets). Normal platelets incubated with autologous plasma for 24 h maintained a Ch/PL ratio of 0.7, whereas this value changed to 1.4 when these cells were incubated with plasma from the patient. These results suggest that platelets of patients affected by AA acquire the same biochemical abnormality as red cells.
Anti‐GMP140 (CD62) autoantibody in a patient with autoimmune thrombocytopenic purpura
Authors: Bierling Philippe , Bettaieb Ali , Fromont Patricia , And Marina Favrin , Duedari Najib 
Published: March 2008

SummaryThe presence of platelet GMP140 (CD62) antibodies was analysed by the MAIPA test in 57 sera from patients with AITP and on platelets from 54 patients with thrombocytopenia of suspected immune origin. A CD62 antibody was found in only one serum. Its specificity was confirmed by an ELISA and a radioimmunoprecipitation procedure using total intact platelets and immuno‐purified GMP140. An increased amount of platelet‐associated (PA) IgG, due to in vivo fixation of GMP140 and GpIIb/IIIa antibodies, was also found on the patient platelet membrane, suggesting that GMP140 autoantibody may contribute to immune platelet destruction. No increase in PAGMP140 antibody was found on the other 54 platelet suspensions.
Subpopulations of CD34‐positive haemopoietic progenitors in fetal blood
Authors: Thilaganathan Baskaran , Nicolaides Kypros H. , Morgan Gareth 
Published: March 2008

SummaryFlow cytometry was used to determine the percentage and number of circulating CD34+ cells in fetal blood from 100 pregnancies at 13‐38 weeks gestation. When expressed as a percentage of the total number of lymphocytes, the proportion of CD34+ cells decreased exponentially from a mean of 11.1% (9.2 x 107/1) at 13 weeks to 1.0% (3.0 x 107/1) at 38 weeks (r = 0.751, P < 0.0001. The use of primitive fetal blood CD34+ progenitor cells for prenatal somatic gene therapy may have distinct advantages over postnatal somatic gene therapy.
Significant amount of hepatocyte growth factor detected in blood and bone marrow plasma of leukaemia patients
Authors: Nakamura Shuji , Gohda Eiichi , Matsuo Yoshinobu , Yamamoto Itaru , Minowada Jun 
Published: March 2008

SummaryHepatocyte growth factor (HGF) has been known as a versatile functional molecule, and as being involved in the colony formation of haemopoietic progenitor cells. Clinically, an elevated HGF level in the blood has been associated with liver diseases such as fulminant hepatic failure and acute hepatitis. We have found a high level of HGF in blood and bone marrow plasma from patients with various types of leukaemia and lymphoma. In particular, 21/31 acute myeloblastic leukaemia (AML) patients showed a significant level of HGF (< 0.40ng/ml) in their blood or bone marrow plasma. The mean value of HGF in the plasma of AML patients was 2.03 ng/ml, which was higher than that in the serum of patients with acute hepatitis. This demonstrates, for the first time, evidence of frequent association of increased levels of HGF in non‐lymphocytic leukaemias, though its significance in the disease remains unknown.
A new type of pseudothrombocytopenia: EDTA‐mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody
Authors: Christopoulos C. G. , Machin S. J. 
Published: March 2008

Summary In vitro agglutination of platelets leading to low automated platelet counts was observed in EDTA‐anticoagulated blood from human volunteers receiving infusions of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb‐IIIa. This pseudothrombocytopenia depended on the presence of chimaeric Fab on the platelet surface and was not seen when sodium citrate was used as anticoagulent. Preliminary evidence suggests that this phenomenon might be mediated by immunoglobulin G reactive with the human component of the chimaeric Fab. It is important to exclude pseudothrombocytopenia when low automated platelet counts are reported in association with the administration of chimaeric anti‐platelet antibodies.
Effects of interleukin‐6 on mobilization of primitive haemopoietic cells into the circulation
Authors: Pettengell Ruth , Luft Thomas , de Wynter Erika , Coutinho Lucia , Young Rosemary , Fitzsimmons Lesley , Scarffe J. Howard , Testa Nydia G. 
Published: March 2008

Summary. Twenty‐seven patients with advanced adenocar‐cinoma were studied. Groups of three patients received interleukin‐6 (IL‐6) in doses ranging from 0.5 to 20 μg/kg by daily subcutaneous injection on days 1–7 and 22–49. Four patients received IL–6 2.5 μg/kg/d with GM‐CSF 5 μg/kg/d and three patients received IL‐6 2.5 μg/kg/d. with IL‐3 5 μg/kg/d. Circulating platelet numbers increased 1.65‐fold during IL‐6 treatment, in a dose‐dependent fashion (P= 0.01). This increase is inferior to that expected from laboratory studies. No significant change in total WBC was seen after IL‐6 alone.After treatment with IL‐6, significant increases in numbers of circulating mononuclear cells (2.2‐fold, P= 0.006) and GM‐CFC numbers (3.2‐fold, P= 0.01) were seen, but there were no changes in circulating megakaryocyts‐CFC numbers. In contrast, after treatment with IL‐6 and GM‐CSF, larger increases in both circulating GM‐CFC (20‐fold, P= 0.04) and megakaryocyte‐CFC numbers (18‐fold, P= 0.03) were seen. Increases in blood progenitors after treatment with IL‐6 and IL‐3 did not achieve statistical significance. The ability of peripheral blood mononuclear cells to generate and sustain long‐term haemopoiesis in vitro was similar in IL‐6‐treated patients to that in untreated control subjects. No significant changes in the incidence of bone marrow progenitors or their cycling status (assessed by thymidine suicide) were seen.These data suggest that IL‐6 alone will not be clinically useful to mobilize blood progenitor cells in cancer patients.
Low plasma heparin cofactor II levels in thalassaemia syndromes are corrected by chronic blood transfusion
Authors: O'DRISCOLL A. , MACKIE I. J. , PORTER J. B. , MACHIN S. J. 
Published: March 2008

Low plasma heparin cofactor II (HCII) levels are associated with a thrombotic tendency, and we have previously shown these to be decreased in a variety of haemolytic conditions. The risk of thrombosis is recognized to be increased in both thalassaemia major (TM) and intermedia (TI), although the exact mechanisms are poorly understood.HCII levels have therefore been compared in 20 untrans‐fused patients with TI and 20 regularly transfused TM patients to determine the influence of transfusion on HCII. Additionally, untransfused TI patients have been commenced on regular red cell transfusion and the effects on correction of low HCII levels investigated. HCII levels were significantly lower in the untransfused TI patients (mean 0–56 – 0–06U/ml) compared to TM patients (mean 0–85 – 0‐lU/ml; P< O'OOl). Levels in TI were significantly less than in healthy age‐matched controls (P < 0–001) and correlated with Hb values (r = 0′8), whereas levels in TMwere at the lower end of the normal range. ATIII values were within the normal reference range in both TI and TM, and HCII antigen showed a parallel reduction to HCII activity, indicating that reduction in HCII is not a consequence of increased thrombin consumption. Three patients with TI were commenced prospectively on hypertransfusion programmes which resulted in a slow normalization of their levels taking 2–3 months.These findings support a hypothesis that the low HCII levels are related to increased red cell turnover and can be normalized once this turnover has been suppressed by hypertransfusion, The thrombotic risk to patients with low HCII levels in the presence of haemolysis might in principle be decreased by such transfusion regimes.
Atypical chronic lymphocytic leukaemia witht(ll;14)(ql3;q32): karyotype evolution and prolymphocytic transformation
Authors: CIINEO ANTONIO , BALBONI MASSIMO , PIVA NADIA , RIGOLIN GIAN MATTEO , ROBERTI MARIA GRAZIA , MEJAK CRISTINA , MORETTI SABRINA , BIGONI RENATO , BALSAMO ROSA , CAVAZZINI PIERLUIGI , CASTOLDI GIANLUIGI 
Published: March 2008

Summary. In order to define better the cytological and clinical features of atypical B‐cell chronic lymphocytic leukaemia (B‐CLL) with t(ll;14)(ql3;q32), sequential morphologic immunological and cytogenetic studies were performed in seven patients belonging to a series of 72 consecutive cases presenting with a diagnosis of CLL or atypical CLL according to the FAB criteria.Cytologic diagnosis in these seven patients with t(ll;14) was typical CLL in two cases presenting with < 10% large lymphocytes (LL) and prolymphocytes (PL) and atypical CLL in five cases in which LL and PL comprised between 10% and 55%. The diagnosis was supported by histologic findings on bone marrow biopsy (five cases) or splenectomy specimens (two cases). A progressive increase of peripheral LL and PL was observed, resulting in a switch of FAB diagnosis over a 6‐60‐month period from typical CLL into atypical CLL in two cases and from atypical CLL into prolymphocytic leukaemia in five cases.Immunophenotyping showed a mature B‐cell phenotype with CD19, CD22, CD24 positivity and CD10 negativity in all patients. A bright‐staining pattern for surface immunoglobulins (SIg) was detected in 6/7 cases, CD5 positivity in 6/7 cases, and CD23 positivity in 1/7 cases. The FMC‐7 monoclonal antibody was positive in >40% cells in 5/6 cases.Chromosome changes in addition to t(11; 14) were seen in five cases; in two cases unbalanced translocations involving the 3q21 chromosome region, resulting in partial trisomy for the long arm of chromosome 3, were detected early in the course of the disease. Karyotype evolution that was associated with disease progression occurred in 3/6 assessable patients.Comparison of these findings with similar data from 65 B‐CLL patients without t(ll;14) showed that atypical morphology, switch of FAB diagnosis during the course of the disease, and karyotype evolution were more frequently seen in cases with t(ll;14) (5/7 v 15/65 cases, P = (V015, 7/7 v 7/65 cases, P < 0‐0001, and 3/6 v 5/45 assessable cases, P= 0‐04, respectively). The frequency of positivity for CD2 3 and bright SIg staining differed significantly in the two groups.It is concluded that t(ll;14) identifies a cytologically atypical subset of B‐CLL, characterized by frequent cytologic and cytogenetic evolution and by a distinct immunological profile, sharing some biological features with mantle cell lymphoma.